SNAP Life Sciences
SNAP Life Sciences provides a SaaS-based exchange platform for pharmaceutical and biotechnology companies to buy, sell, and license drug assets and intellectual property. The platform combines AI-powered valuation tools with a two-sided exchange engine to streamline deal-making, and its database covers over 5,000 biopharma companies and 30,000+ drug assets available for partnering.
- Commerce & Shopping
- Artificial Intelligence
- Software Only
- Data & Analytics
- Biotechnology
- Blockchain & Cryptocurrency
- Drug Discovery & Therapeutics
- Financial Technology
- Healthcare Technology
Funding
Founders
Founder details are not available yet.
Product
Problem
Pharmaceutical and biotechnology companies face a fragmented and opaque process for buying, selling, and licensing drug assets and intellectual property. Traditional deal-making relies on manual research, subjective valuation, and inefficient communication between buyers and sellers, leading to high transaction fees, prolonged negotiations, and missed strategic opportunities.
Solution
SNAP Life Sciences offers a unified, SaaS-based exchange platform that digitizes the entire drug asset and IP transaction lifecycle. The platform provides AI-powered valuation tools that deliver real-time, data-driven assessments based on scientific methodologies and prevailing market conditions. A two-sided exchange engine connects buyers and sellers with a structured, transparent, and collaborative deal-making workflow, while advanced matching algorithms identify strategic partners based on portfolio needs. The integrated suite supports in- and out-licensing, partnering, collaboration, and acquisition, enabling faster, more informed decisions.
Target Audience
Primary customers are pharmaceutical companies, biotechnology firms, and research institutions engaged in drug asset licensing, partnership, and portfolio management.
Features
- Molecule IQ™ AI valuation engine using a proprietary three-factor approach to assess pharmaceutical asset worth
- Two-sided exchange platform for structured, transparent transfer of drug assets and IP
- Strategic matching algorithms connecting buyers and sellers based on portfolio fit and strategic needs
- Real-time market intelligence and dynamic valuation tools incorporating policy changes and market trends
- Centralized portal for in- and out-licensing, collaboration, partnering, and acquisition
- Post-deal outcome analytics and portfolio optimization insights based on prevailing market conditions
- Database covering 5,000+ biopharma companies and 30,000+ drug assets available for partnering